In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Inhale, Pfizer end inhaled insulin deal

Executive Summary

Inhale Therapeutic Systems and Pfizer will collaborate to develop inhalable dry powder insulin products using Inhale's noninvasive pulmonary drug delivery system for macromolecules.
Deal Industry
  • Biotechnology
    • Large Molecule
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Pulmonary
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register